# Pertuzumab

## Perjeta inj 420mg/14mL (sample)

| 藥物代碼           | IPER0                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA.                                                                                                                                                                                                                                         |
| 副作用             | The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) for treatment of breast cancer that has spread to other parts of the body (metastatic) are:DiarrheaHair lossLow levels of white blood cells with or without a feverNauseaFeeling tiredRashDamage to the nerves (numbness, tingling, pain in hands/feet) |
| 禁忌               | PERJETA? (pertuzumab) is approved for use in combination with Herceptin? (trastuzumab) and docetaxel (chemotherapy) in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.                               |
| 藥物保存方式       | 2-8°C                                                                                                                                                                                                                                                                                                                                                  |
| 用法用量           | The initial dose of PERJETA is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes.                                                                                                                                                      |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                           |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                           |
| 懷孕用藥危分級     | 儘量避免                                                                                                                                                                                                                                                                                                                                               |
| 孕期用藥建議       | N/A                                                                                                                                                                                                                                                                                                                                                    |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                    |
| 哺乳期用藥建議     | Human Data Suggest Potential Toxicity                                                                                                                                                                                                                                                                                                                  |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                    |
| 注射劑給藥建議途徑 | IVD                                                                                                                                                                                                                                                                                                                                                    |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                    |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                    |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                    |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                    |
| 注意事項           | 僅可使用0.9%氯化鈉注射液稀釋。不可使用葡萄糖(5%)溶液。                                                                                                                                                                                                                                                                                                 |

## Perjeta inj 420mg/14mL

| 藥物代碼           | IPERJ                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.                                                                                                                                                                                                                                                        |
| 副作用             | The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) for treatment of breast cancer that has spread to other parts of the body (metastatic) are:DiarrheaHair lossLow levels of white blood cells with or without a feverNauseaFeeling tiredRashDamage to the nerves (numbness, tingling, pain in hands/feet) |
| 禁忌               | PERJETA? (pertuzumab) is approved for use in combination with Herceptin? (trastuzumab) and docetaxel (chemotherapy) in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.                               |
| 藥物保存方式       | 2-8°C                                                                                                                                                                                                                                                                                                                                                  |
| 用法用量           | The initial dose of PERJETA is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes.                                                                                                                                                      |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                           |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                           |
| 懷孕用藥危分級     | 儘量避免                                                                                                                                                                                                                                                                                                                                               |
| 孕期用藥建議       | N/A                                                                                                                                                                                                                                                                                                                                                    |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                    |
| 哺乳期用藥建議     | Human Data Suggest Potential Toxicity                                                                                                                                                                                                                                                                                                                  |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                    |
| 注射劑給藥建議途徑 | IVD                                                                                                                                                                                                                                                                                                                                                    |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                    |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                    |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                    |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                    |
| 注意事項           | 僅可使用0.9%氯化鈉注射液稀釋。不可使用葡萄糖(5%)溶液。                                                                                                                                                                                                                                                                                                 |

